tradingkey.logo

Ironwood Pharma jumps after 2026 revenue forecast above estimates

ReutersJan 2, 2026 12:30 PM

Shares of drugmaker Ironwood Pharmaceuticals IRWD.O rise 20.2% to $4.05 premarket

IRWD expects 2026 annual revenue to be in the range of $450 million and $470 million, compared to analysts' estimates of $319.4 million - per data compiled by LSEG

Expects 2026 U.S. net sales for constipation drug, Linzess, in the range of $1.13 billion and $1.18 billion, driven by improved net price and low-single digit percentage demand growth - IRWD

Maintains 2025 revenue forecast to be in the range of $290 million and $310 million vs estimates of $307.1 million

In the last 12 months, stock has slipped 23.9%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI